Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation

Pediatric Drugs

Volumn 14, Issue 5, 2012, Pages 283-294

  Vernon, John A ^a,b   Shortenhaus, Scott H ^c   Mayer, Mark H ^c   Allen, Albert J ^c   Golec, Joseph H ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Children; Legislation; Modelling; Research and development.

Indexed keywords

ACCURACY; ARTICLE; DRUG INDUSTRY; ECONOMIC ASPECT; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HUMAN; LAW; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; SOCIAL ASPECT; UNITED STATES;

DRUG INDUSTRY; DRUG LABELING; GOVERNMENT REGULATION; HUMANS; LEGISLATION, DRUG; MODELS, ECONOMIC; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865356259     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11633590-000000000-00000     Document Type: Article

References (16)

1. Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 2007; 297 5): 480-8
2. Vernon JA, Golec JH, DiMasi J. Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Econ 2010; 19 8): 1002-5
3. Abdullah F, Zhang Y, Lardaro T, et al. Analysis of 23 million US hospitalizations: uninsured children have higher all-cause in-hospital mortality. J Public Health 2010; 32 2): 236-44
4. Nordhaus W. Irving Fisher and the contribution of improved longevity to living standards. Am J Econ Sociol 2005; 64 1): 367-92
5. Murphy K, Topel R. The value of health and longevity. J Polit Econ 2006; 14 5): 871-904
6. Lichtenberg FR. Sources of U.S. longevity increase, 1960-2001. Q Rev Econ Finance 2004; 44 3): 47-73
7. Lichtenberg FR, Virabhak S. Pharmaceutical-embodied technical progress, longevity, and quality of life: Drugs as ''equipment for your health''. Manage Decis Econ 2007; 28: 371-92
8. Vernon JA. Congressional testimony before the U.S. House of Representatives Committee on Energy and Commerce hearing on ''Prescription Drug Price Inflation: Are Prices Rising Too Fast?''. December 8, 2009 [online]. Available from URL: http://democrats.energycommerce.house.gov/Press-111/ 20091208/ vernon-testimony.pdf [Accessed 2012 Apr 30]
9. Vernon JA, Golec JH. Pharmaceutical price regulation: public perceptions, economic realities, and empirical evidence. Washington, DC: American Enterprise Institute, 2009
10. Vernon JA, Golec JH, Lutter R, et al. An exploratory study of FDA new drug approval times, prescription drug user fees, and R&D spending. Q Rev Econ Fin 2009; 49: 1260-75
11. Grabowski H, Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Manage Decis Econ 2007; 27: 1-12
12. Pharmaceutical Research and Manufacturers of America. Pharmaceutical industry profile 2010. Washington, DC: PhRMA, 2010 Mar
13. Golec J, Vernon JA. New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 2003. Managerial Decis Econom 2007; 28 5): 481-3
14. Vernon JA. New evidence on drug research and price controls. Regulation 2004; 27 3): 13-4
15. Scherer FM. The link between gross profitability and pharmaceutical R&D spending. Health Aff Millwood) 2001; 20 5): 216-20
16. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003; 22 2): 151-85